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Abstract
Background: Xenotropic Murine Leukemia Virus-related Virus (XMRV) is a human gammaretrovirus recently
identified in prostate cancer tissue and in lymphocytes of patients with chronic fatigue syndrome. To establish the
etiologic role of XMRV infection in human disease requires large scale epidemiologic studies. Development of
assays to detect XMRV-specific antibodies would greatly facilitate such studies. However, the nature and kinetics of
the antibody response to XMRV infection have yet to be determined.
Results: Three rhesus macaques were infected with XMRV to determine the dynamics of the antibody responses
elicited by infection with XMRV. All macaques developed antibodies to XMRV during the second week of infection,
and the predominant responses were to the envelope protein gp70, transmembrane protein p15E, and capsid
protein p30. In general, antibody responses to gp70 and p15E appeared early with higher titers than to p30,
especially in the early period of seroconversion. Antibodies to gp70, p15E and p30 persisted to 158 days and were
substantially boosted by re-infection, thus, were identified as useful serologic markers. Three high-throughput
prototype assays were developed using recombinant proteins to detect antibodies to these viral proteins. Both
gp70 and p15E prototype assays demonstrated 100% sensitivity by detecting all Western blot (WB) positive serial
bleeds from the XMRV-infected macaques and good specificity (99.5-99.9%) with blood donors. Seroconversion
sensitivity and specificity of the p30 prototype assay were 92% and 99.4% respectively.
Conclusions: This study provides the first demonstration of seroconversion patterns elicited by XMRV infection.
The nature and kinetics of antibody responses to XMRV in primates were fully characterized. Moreover, key
serologic markers useful for detection of XMRV infection were identified. Three prototype immunoassays were
developed to detect XMRV-specific antibodies. These assays demonstrated good sensitivity and specificity; thus,
they will facilitate large scale epidemiologic studies of XMRV infection in humans.
Background
In 2006, a novel gammaretrovirus was identified in
prostate cancer tissue using Virochip DNA microarray
technology [1]. Cloning and sequencing of the gam-
maretrovirus revealed a close similarity to xenotropic
murine leukemia viruses; thus, it was named Xenotro-
pic Murine Leukemia Virus-related virus (XMRV).
Initial screening using a nested reverse transcription-
PCR (RT-PCR) assay found that XMRV was detectable
in 10% (9/86) of tumor tissues from prostate cancer
patients [1]. Subsequent studies revealed several
important insights regarding XMRV: (a) infectious
virus was produced from prostate cancer cell lines
transfected with an XMRV genome derived from 2
cDNA clones, (b) the virus replicated in both prostate
and non-prostate cell lines, (c) XMRV replication in
the prostate cancer-derived cell line, DU145, is inter-
feron sensitive, and (d) a human cell surface receptor
required for infection with XMRV is xenotropic and
polytropic retrovirus receptor 1 [2]. Finally, the charac-
terization of integration sites in human prostate DNA
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XMRV to infect humans [3].
Indeed, the association between XMRV and prostate
cancer was strengthened by recent studies demonstrat-
ing the presence of XMRV DNA as well as viral proteins
in prostate cancers [4,5]. Using a quantitative PCR and
immunohistochemistry, Schlaberg et al.f o u n dX M R V
DNA in 6% and XMRV proteins in 23% of 233 tissues
from prostate cancer patients [4]. Moreover, XMRV was
found at a higher frequency in higher grade or more
aggressive cancers [4]. Recently, XMRV has been also
identified in 67% (68/101) of patients with chronic fati-
gue syndrome in the United States (U.S.) [6]. In con-
trast, another U.S. study reported the absence of XMRV
in either CFS patients (0/50) or healthy controls (0/56)
[7]. Furthermore, studies conducted in Northern Europe
indicate a much lower or zerop r e v a l e n c eo fX M R Vi n
patients with prostate cancer [8,9] or with CFS [10-12].
Whether the discrepancies are due to differences in the
geographic distribution of XMRV, technological differ-
ences between the assays used, clinical criteria for CFS
patient selection, or genetic divergence of XMRV
remains to be determined.
Gammaretroviruses are well-known pathogens causing
leukemia, neurological disease, and immunodeficiency in
mice, cats and some non-human primates [13,14]. As
XMRV is the first reported human gammaretrovirus, its
existence raises many questions with regard to the etio-
logic role of XMRV in prostate cancer and/or its asso-
ciation with CFS and other human diseases, its mode of
transmission, and its geographic distribution. Addressing
these questions requires epidemiologic studies in large
cohorts of patients with prostate cancer, CFS and other
t y p e so fd i s e a s e sa sw e l la si nt h eg e n e r a lp o p u l a t i o n .
The relatively cumbersome nature of molecular technol-
ogies such as DNA microarrays, fluorescence in situ
hybridization (FISH), reverse transcriptase polymerase
chain reaction (RT-PCR) and PCR presents a significant
challenge to executing such studies. Thus, high-through-
put serologic assays that detect XMRV-specific antibo-
dies would be of great value.
Since its discovery, XMRV has been partially charac-
terized at the molecular and cellular level [1-3,15-18].
However, there is very limited information available
regarding the viral life cycle, replication dynamics, tissue
tropism, and the host immune response to XMRV infec-
tion. In fact, the nature and kinetics of antibody sero-
conversion induced by infection with XMRV have yet to
be determined. This information is essential for the
development of optimal XMRV-antibody screening
assays.
To learn more about XMRV infection and potential
serologic markers, rhesus macaques were experimentally
infected with XMRV to establish an animal model for
studying viral replication kinetics, tissue tropism, and
the immune response [19]. The present study focuses
on the characterization of antibody responses to XMRV
infection and the identification of serologic markers use-
ful for detection and screening. Furthermore, this study
also describes the development of high-throughput pro-
totype immunoassays for the detection of XMRV-speci-
fic antibodies.
Results
XMRV Viral Proteins
XMRV proteins were identified by Western blot (WB)
analysis using goat polyclonal antibodies to Friend-
MuLV (anti-MuLV pAb) and to envelope glycoprotein
gp69/71 of Rauscher-MuLV (anti-Env pAb). Because
XMRV shares >90% overall nucleotide sequence identity
with known MuLVs, the anti-MuLV pAb detected all
structural proteins of XMRV. The four mature core pro-
teins derived from the gag gene, termed matrix (MA,
p15), p12, capsid (CA, p30), and nucleocapsid (NC, p10)
showed clearly resolvable bands on WB at molecular
weights approximating the sequence prediction: MA at
15 kDa, p12 at 10 kDa, CA at 30 kDa and NC at 6 kDa
(Figure 1A). In addition, the gag precursor (p68/p80)
and proteolysis intermediate (p12-CA) were also
detected. The transmembrane subunit (TM, p15E) of
envelope protein showed a resolved band at 14 kDa on
WB, although the sequence predicted molecular weight
is 19.6 kDa (Figure 1A). The lower than predicted MW
on SDS gel could be due to the elongated helical struc-
ture of TM protein [20]. The envelope protein gp70 was
not clearly resolvable by the anti-MuLV pAb due to
antibody binding to the gag precursor p68/p80 obscur-
ing the region between 62 and 80 kDa. However, gp70
was clearly detected using the anti-Env pAb, showing
diffuse doublet bands at ~70 kDa (Figure 1A).
The identity of XMRV structural proteins was further
confirmed by competitive inhibition with recombinant
XMRV proteins. E. coli expressed recombinant proteins,
p 1 5( M A ) ,p 1 2 ,p 3 0( C A ) ,p 1 0( N C )a n dp 1 5 E( T M ) ,
were used to competitively inhibit the anti-MuLV pAb
binding to the corresponding native proteins on WB. As
shown by Figure 1B (strips 2-6), band intensity of the
native proteins decreased by 90-100% in the presence of
the corresponding recombinant proteins confirming the
banding positions for the native viral proteins: p15, p12,
p 3 0 ,p 1 0a n dp 1 5 E .T h eb a n d i n gp o s i t i o no fg p 7 0w a s
confirmed by competitive inhibition of the anti-Env pAb
with mammalian expressed gp70 protein as shown by
Figure 1B (strip 8).
In summary, the data demonstrate that XMRV virions
produced from prostate cancer cell line DU145 contain
the four mature core proteins (p15, p12, p30, p10), and
the two envelope proteins (gp70 and p15E). In addition,
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all structural proteins of XMRV.
Analysis of antibody response in XMRV-infected rhesus
macaques
Serial bleeds from XMRV inoculated macaques were
first analyzed by WB using native viral proteins. All
three macaques developed XMRV-specific antibody
responses during the second week post infection (PI).
Figure 2A shows a representative antibody pattern
(macaque RIl-10) during seroconversion of the XMRV-
infected macaques and XMRV viral RNA and proviral
DNA results [19]. The predominant antibody responses
were to gp70, p15E and p30. The anti-gp70 response
was first detected on day 9 PI, showing reactivity at 70
kDa. The anti-p15E response was first detected on day
11 PI and the anti-p30 response on day 14-18 PI in all
three macaques. In addition, a weak antibody response
to p15 (MA) was evident between days 28-35 PI in all
macaques. Two macaques (RLq-10 and RYh-10) also
developed weak and transient antibodies to p10 (NC)
detectable from days 14 to 35 PI (data not shown).
The antibody response to gp70 was confirmed by WB
using mammalian expressed recombinant gp70 antigen.
As shown in Figure 2B, serial bleeds of RIl-10 from days
9 to 134 specifically bound to the recombinant antigen
at 70 kDa. Specificity of the antibody responses to p15E
and p30 was also confirmed by complete inhibition of
binding to the native proteins in the presence of corre-
sponding p15E or p30 recombinant proteins (data not
shown). Of note, several major bands between 49 to 62
kDa (Figure 2A) that became substantially more intense
on day 9 PI were subsequently confirmed to be human
cellular proteins based on competitive inhibition studies
utilizing uninfected DU145 cell lysate proteins (data not
shown).
To determine the magnitude and the duration of the
predominant antibody responses to XMRV, E. coli
expressed recombinant antigens p15E, p70 and p30
were used to develop three indirect chemiluminescent
immunoassays (CMIAs) on the automated ARCHI-
TECT® instrument system. Serial bleeds of the XMRV-
infected macaques were analyzed by the indirect (anti-
human IgG) CMIAs (Figure 3). All three macaques
developed detectable antibody responses to p15E, p30
and p70 from days 9-18 PI (cutoff = signal ≥3t i m e so f
day 0 signal). Antibody titers increased to peak levels
between days 74-95 and remained relatively stable to
day 144 for RLq-10 (day of sacrifice) and day 158 for
RIl-10 and RYh-10. After the second XMRV inoculation
(day 158), the antibody responses were boosted substan-
tially; the titers gradually decreased to basal levels and
were maintained through day 275 PI.
Compared to the native viral protein-based WB, the
indirect p15E assay was more sensitive. The assay
detected all anti-p15E WB positive serial bleeds as well
as the day 9 WB negative bleeds of all three macaques.
The indirect p30 assay sensitivity and WB were similar;
anti-p30 responses were detected on day 11 for RLq-10
and day 18 for RIl-10 and RYh-10. However, the indir-
ect p70 assay was less sensitive than WB, initially detect-
ing the day 11 bleed for RLq-10 and day 18 bleed for
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Figure 1 XMRV viral proteins. (A) XMRV viral proteins identified by WB analysis using goat polyclonal antibodies to Friend MuLV (anti-MuLV) at
a 1:2000 dilution and to Env (gp69/71) of Rauscher-MuLV (anti-Env) at a 1:1000 dilution. Env, Envelope protein; TM, Transmembrane protein; MA,
Matrix protein; CA, Capsid protein; and NC, Nucleocapsid protein. The gag precursor (p68/p80) and proteolysis intermediate (p12-CA) are
italicized. (B) Competitive inhibition of anti-MuLV (Strips 2-6) and anti-Env (Strip 8) binding to native XMRV proteins on WB strips with
recombinant XMRV proteins. Inhibitors of recombinant proteins and concentrations for specific strips are listed in the inserted table.
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Page 3 of 16RIl-10 and RYh-10, 2-9 days later than the WB. Signals
o ft h ep 7 0a s s a yw e r es u b s t a n t i a l l yl o w e ra sc o m p a r e d
to signals of the p15E assay, perhaps due to incorrect
folding of E. coli expressed p70 antigen which lacks
glycosylation.
Development of XMRV antibody assays
Although the three indirect p15E, p70 and p30 assays
were sufficient to characterize antibody responses in the
XMRV-infected macaques, they were not suitable for
large scale epidemiologic studies in humans due to 3-5
fold higher background signals. Consequently, a direct
assay format was used to improve detection specificity.
In addition, the E. coli expressed p70 antigen was
replaced with mammalian expressed gp70 recombinant
protein in combination with signal amplification to
improve assay sensitivity.
Using the E coli expressed recombinant proteins, p15E
and p30 and mammalian expressed gp70, three direct
CMIAs were developed for the automated ARCHI-
TECT® instrument system. All assays utilized a direct
format where recombinant proteins were used for both
capture and detection to form a double antigen sand-
wich with anti-p15E, anti-gp70 or anti-p30 antibodies.
Specificity and sensitivity of the prototype assays were
evaluated on blood donor samples (negative for other
known bloodborne pathogens, presumed negative popu-
lation) and the seropositive serial bleeds from the
XMRV-infected macaques (positive population).
Figure 4 summarizes the results from sensitivity eva-
luation of both direct and indirect p15E CMIAs with
39 serial bleeds (days 4-144/158 PI) from XMRV-infected
macaques, RIl-10, RLq-10 and RYh-10. Both the direct
and indirect p15E assays detected 36 of 39 serial bleeds
(days 9-144/158 PI); day 4 bleeds from each of the three
macaques were negative in both assays. However, the
direct p15E CMIA demonstrated better seroconversion
sensitivity by generating significantly higher signals for
the early IgM response (days 9-14 PI) in all three maca-
ques, and better or equivalent sensitivity for the subse-
quent serial bleeds of RIl-10 and RYh-10.
The most significant advantage realized by utilization
of the direct format assays is the improvement in speci-
ficity. This was demonstrated by a comparison between
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Figure 2 XMRV seroconversion in RIl-10. (A) Representative antibody responses detected by WB using native XMRV proteins (4 μg/strip) and
(B) using mammalian expressed recombinant gp70 (~1.8 μg/strip). Plasma samples from macaque RIl-10 are listed on strips as days post
inoculation (PI) with XMRV (0-134). Arrows indicate the first day that detectable reactivity was observed for specific viral proteins. XMRV viral RNA
and proviral DNA results [19] are listed above the WB strips. The anti-MuLV pAb (a-F) was used as a positive control. The thin faint band at day
0 in Figure 2B most likely represents non-specific reactivity.
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donor samples. In the indirect p15E CMIA, signals of
the blood donors were high (mean of 3275 RLU) with
unacceptably broad distribution (standard deviation, SD,
of 7019 RLU). The broad signal distribution resulted in
poor separation between the negative population (100
blood donors) and the positive population (36 XMRV
seropositive macaque bleeds). As shown in Figure 5A,
based on a cutoff level set to detect all 36 XMRV sero-
positive bleeds, 25 of the 100 blood donors would be
considered as false positive, resulting in an assay specifi-
city of 75%. In contrast, the same 100 blood donor sam-
ples tested in the direct p15E CMIA had substantially
reduced signals (mean of 446 RLU) and a far tighter
distribution (SD of 38 RLU). An additional 780 blood
donor samples were tested in direct p15E CMIA.
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Figure 3 Time course of XMRV-specific antibodies in macaques. Detection of XMRV-specific antibodies in RIl-10, RYh-10 and RLq-10 using
the recombinant protein (p15E, p70 or p30) based indirect chemiluminescent immunoassays (CMIAs). Macaque RLq-10 was sacrificed at 144
days. RLU, relative light units. Arrows indicate the XMRV-infection and immunization time points. The insets show anti-p30 and anti-p70
responses following 1
st infection on an expanded CMIA signal scale.
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Page 5 of 16Results obtained from the total 880 blood donor sam-
ples (set 1) showed a tight signal distribution with a
mean of 383 RLU and SD of 100 RLU. Consequently,
the 36 XMRV seropositive bleeds were clearly separated
from the 880 negative blood donors (Figure 5B), result-
ing in 100% (36/36 XMRV macaque seropositive bleeds)
sensitivity and markedly improved specificity of 99.9%
(879/880). One donor sample (p81) was reactive (5059
RLU) by the direct p15E CMIA, but was negative by
WB using viral lysate proteins (Additional file 1, section
A1). To further evaluate assay specificity, specimens
from 110 retrovirus infected humans (100 HIV-1,
human immunodeficiency virus type I and 10 HTLV-I/
II, human T-cell lymphotropic virus) were tested in the
direct p15E CMIA. All were found to be non-reactive
(data not shown).
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Figure 4 Sensitivity comparison between the direct and indirect p15E CMIAs. Comparison between direct and indirect p15E CMIAs for
detection of XMRV p15E-specific antibodies in RIl-10, RYh-10 and RLq-10. The IgM response was confirmed using an anti-human IgM specific
conjugate in the indirect assay format.
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ated with 29 serial bleeds from the 3 XMRV-infected
macaques (diluted to 1:10 with negative human plasma).
As compared to the indirect p70 CMIA, detection sensi-
tivity was greatly enhanced (Figure 6A). The direct gp70
CMIA demonstrated 100% sensitivity by detecting 1:10
dilutions of all 29 serial bleeds (days 9-134/144 PI)
including 5 early bleeds (day 9 for RLq-10 and day 11
and 14 for both RIl-10 and RYh-10) that were not
detected even when tested undiluted in the indirect p70
CMIA. The direct gp70 CMIA also exhibited good sero-
conversion sensitivity by detecting the early IgM
response (days 9-14 PI) from all three macaques (Figure
6A). Since the recombinant gp70 protein contains a 6-
histidine (His) tag sequence, analytical sensitivity of the
direct assay could be determined using anti-His mono-
clonal antibody (anti-His Mab). Anti-His Mab was
diluted in negative human plasma to concentrations of
100, 10 and 1 ng/ml and tested. As shown in Figure 6B,
anti-His Mab could be detected at a level of 6.3 ng/ml
or 39 pM. Assay sensitivity was also evaluated using
end-point dilution analysis of anti-Env pAb. Using serial
2-fold dilutions in negative human plasma, the detection
limit of the assay was estimated at 1:10,000 for this
antiserum.
Specificity of the direct gp70 CMIA was evaluated on
a population of 397 blood donor samples (set 2). The
signal distribution had a mean of 119 RLU and SD of
72 RLU. Three donor samples had signals above the
assay cutoff of 1000 RLU; one (s44) had gp70 WB reac-
tivity using recombinant gp70 antigen (Additional file 1,
section A4). Excluding the WB reactive sample, specifi-
city of the direct gp70 CMIA was estimated at 99.5%
(394/396). The gp70 CMIA also showed substantial dis-
crimination between the blood donor negative popula-
tion and the 29 XMRV seropositive macaque bleeds
even when diluted 1:10 (Figure 7).
Sensitivity of the direct p30 CMIA was initially evalu-
ated using serial 10-fold dilutions of monoclonal anti-
body to MuLV p30 (anti-p30 Mab) or His (anti-His
B:  Direct p15E assay: 100% (36/36) sensitivity, 99.9% (879/880) specificity
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Figure 5 Assay performance comparison between the direct and indirect p15E CMIAs. (A) Signal distribution of the indirect format p15E
CMIA (diagram shown) on 36 XMRV seropositive macaque bleeds and 100 blood donors. (B) Signal distribution of the direct format p15E CMIA
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Page 7 of 16Mab). By linear regression, the detection limits were
estimated to be 0.56 nM for the anti-p30 Mab and 1.18
nM for the anti-His Mab. As compared to the 39 pM
detection limit of the direct gp70 CMIA for the anti-His
Mab, the direct p30 CMIA is ~30-fold less sensitive.
Seroconversion sensitivity was subsequently evaluated
with 9 serial bleeds of RIl-10 from days 14 to 158 post
the 1
st infection. Although the assay failed to detect the
two early bleeds (days 14 and 18) that were positive by
WB, it detected the remaining 7 bleeds. An additional
16 serial bleeds from RIl-10 and RYh-10 (days 5 to 52
post the 2
nd infection) were detected at a 1:10 dilution.
Thus, the overall seroconversion sensitivity was 92%
(23/25).
Specificity of the direct p30 CMIA was evaluated with
a different set of 985 blood donor samples (set 3). Dis-
tribution of the assay values for the donor population
had a mean of 420 RLU with SD of 195 RLU. The SD
was 2-fold greater than the SD obtained using the direct
p15E (SD = 100) and gp70 (SD = 72) CMIAs (Figure 8).
Eight samples had values above the assay cutoff of 2000
RLU. Two of the 8 reactive donor samples (s176 and
p43) had p30 WB reactivity (Additional file 1, section
A3). Excluding the 2 WB reactive samples, specificity of
the direct p30 CMIA was estimated at 99.4% (977/983).
Due to broader distribution of the negative donor
population and lower sensitivity in the early period of
seroconversion, the direct p30 CMIA showed less discri-
mination between the negative donor and XMRV sero-
positive populations as compared to the direct p15E and
gp70 CMIAs (Figure 8).
The 12 blood donor samples that were initially reac-
tive in either the direct p15E, gp70 or p30 assay were
re-tested in all the three direct CMIAs. Results are sum-
marized in Table 1. In contrast to antibody responses in
the XMRV infected primates that had high reactivity to
all 3 proteins (S/CO ranges: 10-82 for p15E, 15-292 for
gp70, 2.5-49 for p30), the blood donors showed low
levels of detectable antibodies (S/CO < 3.7) and reactiv-
ity to only a single protein (either p15E, gp70 or p30)
(Table 1). Based on WB analysis with viral lysate, two
p30 CMIA reactive donor samples had anti-p30 reactiv-
ity (Additional file 1, section A3). A third donor had
anti-gp70 reactivity on recombinant gp70 WB (Addi-
tional file 1, section A4). The lack of availability of
PBMC or whole blood as well as plasma or serum from
the 12 unlinked blood donors precluded attempts to
confirm XMRV infection by PCR. Consequently, the 3
WB reactive blood donor samples were excluded from
assay specificity calculations; the remaining 9 donor
samples were designated as false positive for assay speci-
ficity calculations (Table 1).
Anti-His Mab ( ng/ml)
y = 131.42x + 172.8
R
2 = 0.9993
0
500
1000
1500
02468 1 0
Detection limit
~ 6.3 ng/ml (39 pM)
C
M
I
A
 
S
i
g
n
a
l
 
(
R
L
U
)
A B
0
100000
200000
300000
400000
500000
0 25 50 75 100 125 150
Days post Infection
RIl-10 RLq-10 RYh-10
IgM
C
M
I
A
 
S
i
g
n
a
l
 
(
R
L
U
)
Figure 6 Sensitivity evaluation of the direct gp70 CMIA. (A) Detection of XMRV gp70-specific antibodies in RIl-10, RYh-10 and RLq-10 by the
direct gp70 CMIA. All samples were diluted to 1:10 with negative human plasma prior to the testing. (B) Linear regression of signals at 10, 1 and
0 ng/ml of anti-His monoclonal antibody. Detection limit was determined based on the linear fitting equation with a cutoff value of 1000 RLU.
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infected macaques
To further characterize the predominant responses in
XMRV-infected macaques, antibody titers of selected
serial bleeds were determined using the 3 prototype
direct CMIAs (Table 2). As expected, antibody titers
correlated well with signals (RLU) of the CMIAs. After
the initial infection, all 3 macaques showed similar titers
for anti-gp70 and anti-p15E responses. However, RLq-
10 had considerably lower titers for the anti-p30
response as compared to RIl-10 and RYh-10. Antibody
titers to all three proteins were substantially boosted
after the 2
nd inoculation with XMRV. The final immuni-
zation with a cocktail of recombinant XMRV proteins
also boosted the anti-p15E titer by 10-fold and anti-p30
titer by 2.5 to 5-fold, but had no discernable impact on
the anti-gp70 titer.
A comparison of the magnitude of antibody
responses to each of 3 XMRV proteins is complicated
by the difference in sensitivity between the three pro-
totype assays. Moreover, the interpretation of WB
results obtained using XMRV viral lysate may be com-
promised due to disparities in the quantity of each
protein. In an effort to circumvent these issues, WB
strips were prepared with recombinant proteins gp70,
p15E and p30 at normalized concentrations of 90
pmole for each protein. WB reactivity of the day 42,
134, and 167 bleeds correlated with the CMIAs results.
Notably, the anti-p15E response was as strong as the
anti-gp70 response in all selected bleeds evaluated
(Figure 9); both were present at days 42 and 134 and
were boosted by re-infection (day 167). Anti-p30 reac-
tivity was barely detectable at day 42 and 134 and was
substantially boosted post-reinfection (day 167). These
results confirmed that antibody responses to gp70 and
p15E were dominant.
Based on the WB data obtained using XMRV viral
lysate (Figure 1A), it was of interest to examine antibody
titers of anti-MuLV pAb using the CMIAs. Anti-MuLV
pAb contains high antibody titers to all three proteins,
gp70, p15E and p30 (Table 2). Notably, the anti-p30
titer is ~100-fold higher than the titers present in the
XMRV-infected macaques, presumably reflecting differ-
ences between antibody responses elicited by infection
and immunization.
Discussion
T h ep r i m a r yo b j e c t i v e so ft h ep r e s e n ts t u d yw e r et o
characterize the antibody response elicited by infection
with XMRV and to develop high-throughput antibody
assays suitable for large scale epidemiologic studies of
XMRV infection. Since well-characterized XMRV anti-
body positive human specimens and seroconversion
panels are currently unavailable, the utilization of a non-
human primate model of XMRV infection provides a
bona fide source of positive control sera and seroconver-
sion samples useful for assay optimization and
validation.
Direct gp70 antibody assay: 100% (29/29) sensitivity, 99.5% (394/396) specificity
29 XMRV positive bleeds 
at 1:10 dilution
Log N of RLU
394 blood donors 3 blood 
donors
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e
q
u
e
n
c
y
Cutoff =6.9 (1000 RLU) = Mean + 12SD
Figure 7 Assay performance of the direct gp70 CMIA. Signal distribution of the direct gp70 CMIA on 29 XMRV seropositive macaque bleeds
(diluted 1:10) and 397 blood donors. The box plot shows selected quantiles of continuous distributions (box), the median value (vertical line),
the mean of 394 blood donors and 95% confidence interval (diamond). Signals of the 29 XMRV seropositive bleeds at 1:10 dilution were the
same as plotted in Figure 6A. Log N of RLU, natural log transformation of RLU.
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body response in humans following infection with
XMRV. Several studies have reported detection of rela-
tively low levels of neutralizing antibody or antibody
cross-reactive to the surrogate envelope protein of
Friend Spleen Focus Forming Virus (SFFV) in patients
with prostate cancer, CFS, or blood donors [5,6,11].
Unfortunately, WB confirmation data is not available on
these samples. Using recombinant based WB analysis of
serum from prostate cancer patients and blood donors,
Furuta et al. detected no antibody reactivity to XMRV
envelope protein but occasional reactivity to XMRV gag
protein [21]. Interpretation of these data is complicated
by the lack of information regarding XMRV seroconver-
sion patterns and suitable control reagents to determine
assay sensitivity and specificity.
The present study provides the first demonstration of
seroconversion patterns in primates following infection
with XMRV and characterizes the nature and kinetics of
the antibody response. All three experimentally infected
macaques seroconverted to XMRV. The predominant
antibody responses were directed against gp70, p15E
and p30. Specific antibodies to gp70 and p15E appeared
earlier during seroconversion and reached the highest
titers. These characteristics are similar to the antibody
responses elicited by MuLVs in mice [22-24]. Previous
studies showed that both naturally occurring and vac-
cine induced responses to endogenous MuLVs were pre-
dominantly antibodies against gp70 and p15E [22-24].
Although antibody to p30 could be detected in certain
mouse strains, the titers were lower relative to anti-gp70
or anti-p15E [23]. In addition, a primate model to assess
potential risk of retroviral-mediated gene therapy also
showed similar antibody responses to amphotropic
Direct p30 antibody assay: 92% (23/25) sensitivity, 99.4% (977/983) specificity
14 XMRV positive bleeds 
at 1:10 dilution
9 neat XMRV positive 
bleeds
Log N of RLU
977 blood donors
F
r
e
q
u
e
n
c
y
Cutoff =7.6 (2000 RLU) = Mean + 8.5SD
8 blood 
donors
Figure 8 Assay performance of the direct p30 CMIA. Signal distribution of the direct p30 CMIA on XMRV seropositive macaque bleeds (9
neat and 14 diluted 1:10) and 985 blood donors. The box plot shows selected quantiles of continuous distributions (box), the median value
(vertical line), the mean of 977 blood donors and 95% confidence interval (diamond). Log N of RLU, natural log transformation of RLU.
Table 1 Serologic characterization of XMRV CMIA
reactive blood donors
Donor
ID
p15E
CMIA
p30
CMIA
gp70
CMIA
WB Designation
for
specificity
calculation
S/CO S/CO S/CO Viral
Lysate
gp70*
p81 2.5 0.14 0.12 - nt** false positive
s44 0.2 0.16 2.6 - gp70
band
excluded
s52 0.1 0.17 2.2 - - false positive
p52 0.1 0.15 3.6 - - false positive
p62 0.3 1.0 0.11 - nt false positive
s176 0.3 1.1 0.13 p30 band nt excluded
p43 0.2 1.2 0.12 p30 band nt excluded
s161 0.3 1.7 0.13 - nt false positive
s12 0.2 1.7 0.12 - nt false positive
s88 0.2 1.8 0.13 - nt false positive
s210 0.2 3.7 0.12 - nt false positive
p228 0.3 3.7 0.12 - nt false positive
* Mammalian expressed recombinant gp70
** not tested
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Page 10 of 16MuLV [25]. In this study, 5 rhesus macaques experi-
mentally infected with amphotropic MuLV developed
antibodies to gp70 and p30 (anti-p15E response was not
examined) that persisted through the last day tested
(337-696 PI). Viral infection was also confirmed by PCR
amplification of proviral DNA in peripheral blood
mononuclear cells and lymph node tissue. However, the
time course and titers of these specific antibody
responses were not determined.
Notably, the well-characterized antibody responses in
humans infected with HIV and HTLV are also primarily
to the envelope proteins (HIV-gp120, HTLV-gp46), trans-
membrane proteins (HIV-gp41, HTLV-gp21), and core
proteins of capsid and matrix (HIV-p24 and p17, HTLV-
p24 and p19). Antibodies to envelope and transmembrane
proteins were identified as the early and sustained serolo-
gic markers of infection [26-29]. These markers are the
primary targets utilized by current third generation HIV
and HTLV antibody assays as well as fourth generation
HIV antigen/antibody combination assays for diagnostic
testing and blood donor screening [30-33].
Taken together, the antibody responses to XMRV
observed in this study are consistent with responses
reported for other retroviruses. Thus, antibody responses
to gp70, p15E and p30 represent potentially useful sero-
logic markers for detection of XMRV infection.
Based on the identification of key serologic markers,
prototype direct format CMIAs were developed using
the recombinant proteins gp70, p15E or p30. The assays
all showed good specificity (99.4-99.9%) with blood
donor samples. Both gp70 and p15E prototype assays
demonstrated 100% sensitivity by detecting all WB posi-
tive bleeds from XMRV-infected macaques. Seroconver-
sion sensitivity of the p30 assay was slightly lower due
to the combination of reduced analytic sensitivity and
the delayed kinetics of the anti-p30 response. However,
the p30 assay detects antibody to the core protein dis-
tinct from envelope proteins, thus, may still have value
for confirmation of XMRV infection. Ideally, sensitivity
and specificity of these prototype assays would be
further validated using bona fide XMRV positive and
negative human specimens once they become available.
Due to the high sequence homology, the assays
described herein detect antibody responses not only to
XMRV but also to other known MuLVs. Both the p15E
and p30 prototype assays detected highly diluted
(1:32,000 and 1:64,000) goat antibody to Friend MuLV.
This is consistent with the high sequence homology of
p15E (76%) and p30 (89%) proteins between XMRV and
Friend MuLV. Interestingly, the gp70 assay was also
able to detect the highly diluted antibodies to Friend
MuLV (1:16,000) and Rauscher MuLV (1:10,000) despite
lower sequence homology (59%) between the envelope
proteins of these viruses. This suggests that the most
conserved C-terminal domain of gp70 may represent the
immunodominant region of the envelope protein.
In contrast to HIV and HTLV infection in humans
that generally stimulate strong and sustained antibody
responses, XMRV infection in macaques elicited detect-
able but less robust antibody responses. Re-infection
with XMRV substantially boosted antibody titers; how-
ever, the titers decreased to a basal level by 110 days.
T h el e s sv i g o r o u sa n t i b o d yr e s p o n s em a yr e f l e c tar e l a -
tively low level of XMRV replication in macaques. This
is consistent with the observation that only two (RIl-10
and RYh-10) of three chronically infected macaques had
a detectable but low level plasma viremia (peak levels of
7,500 and ~2,000 copies/ml, respectively) after initial
i n f e c t i o n ,a n di tw a so fs h o r td u r a t i o n[ 1 9 ] .M o r e o v e r ,
although all three macaques had detectable provirus in
PBMC, by 30 days PI XMRV was very difficult to detect
in this compartment (Figure 2A) Of note, XMRV was
detectable in various organsa n dt i s s u e st h r o u g h o u ta9
month follow-up using PCR, FISH and immunohisto-
chemistry [19]. Interestingly, a similar pattern of anti-
body response was also observed in HTLV-I infected
pig-tailed macaques [34]. The boosted HTLV-I antibody
Table 2 Antibody titers of predominant responses in
selected bleeds of XMRV-infected macaques and goat
polyclonal antibodies to MuLV
Sample Days post XMRV Infection Antibody Titers by
ARCHITECT CMIAs
1
st
Infection
2
nd
Infection
Immuni-
zation
Anti-
gp70
Anti-
p15E
Anti-
p30
RIl-10 42 800 40 2
134 3,200 160 10
167 9 128,000 12,800 640
210 52 32,000 800 80
291 133 16 16,000 8,000 4,000
RYh-10 42 1,600 80 10
134 1,600 80 10
167 9 32,000 6,400 640
210 52 8,000 400 80
291 133 16 4,000 4,000 2,000
RLq-10 42 800 80 1
134 800 160 1
Anti-MuLV pAb 16,000 32,000 64,000
Anti-Env pAb 10,000
Anti-His Mab 0.039
nM
1.18
nM
Anti-p30 Mab 0.56
nM
Antibody titers were determined by the three direct gp70, p15E and p30
CMIAs on samples serially diluted with negative normal human plasma, and
expressed as the reciprocal of the bleed dilution giving a reactive result. For
comparison, detection limits of the anti-His and anti-p30 monoclonal
antibodies were also listed.
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Page 11 of 16responses decreased to a basal level approximately 60
days following the 2
nd HTLV-I infection but remained
relatively stable over the next 8 months. Thus, the rela-
tively weak and less sustained antibody responses
observed in XMRV-infected macaques may not reflect
what typically occurs in humans. Further investigations
are needed to determine the level and duration of anti-
body responses in XMRV-infected humans.
Conclusions
In summary, antibody responses elicited by XMRV-
infection in the non-human primate model were fully
characterized. The predominant responses to envelope
protein gp70, transmembrane protein p15E, and capsid
protein p30 were identified as useful serologic markers
for detection of XMRV infection. Three high-through-
put prototype antibody assays detecting these markers
were also developed. The gp70 and p15E assays both
demonstrated excellent sensitivity and specificity; thus,
they will facilitate large-scale epidemiologic studies of
XMRV infection in humans.
Methods
XMRV Virions
XMRV was cultured and purified by Advanced Bio-
t e c h n o l o g i e s ,I n c .( A B I ,C o l u m b i a ,M D ) .B r i e f l y ,X M R V
(VP62)-infected DU145 prostate cancer cells [2]
obtained from the Cleveland Clinic (Cleveland, OH)
were cultured in RPMI medium 1640 supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 200
units penicillin G and 200 μg/ml streptomycin. Virus
from the culture supernatants was purified by sucrose
gradient centrifugation.
Animals and virus inoculations
Three young adult rhesus macaques (>3 years old; >6 kg
body weight) were selected from the Yerkes National
Primate Research Center colony of Emory University.
These included two males (RIl-10 and RLq-10) and one
female (RYh-10). All three macaques were seronegative
for antibodies to Simian immunodeficiency virus (SIV),
Simian retrovirus (SRV) and Simian T-cell leukemia
(STLV) and lacked cross-reactive antibodies to XMRV
based on WB analysis using XMRV viral lysate.
After collection of baseline samples, each of the maca-
ques was inoculated intravenously on day 0 with 10 ml
of DU145 cell culture supernatant containing 3.6 × 10
5
TCID50/ml XMRV. One macaque (RLq-10) was sacri-
ficed on day 144. To ensure persistent infections, 2
macaques (RIl-10 and RYh-10) were re-inoculated on
day 158 with 3.6 × 10
6 TCID50 of purified XMRV virus.
These 2 macaques were subsequently immunized on
gp70 (Env)
RIl-10 RYh-10 RLq-10
167 134 42 167 134 42 134 42 Day PI
p30 (CA)
p15E (TM)
A
B
C
Figure 9 Comparative reactivity for the predominant antibody responses. Analysis of antibody responses in selected bleeds of RIl-10, RYh-
10 and RLq-10 using WB strips prepared with recombinant proteins (90 pmole/protein): A, gp70 (4.4 μg/strip), B, p15E (4.1 μg/strip) and C, p30
(3.1 μg/strip). Plasma samples were listed on strips as days post inoculation (PI) with XMRV.
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Page 12 of 16day 275 with 0.308 ml of recombinant XMRV proteins
including p15 (2.3 μmole), p12 (1.1 μmole), p30 (3.1
μmole), p10 (2.9 μmole), p15E (3.8 μmole) and p70 (1.4
μmole) in incomplete Freund’s adjuvant and sacrificed
on day 291.
Blood was collected from each primate on days 0, 4, 5,
7, 9, 11, 14, 18, 21, 28, 35, 42, 56, 74, 95, 115, 134, 144,
158 post 1
st inoculation and on days 3, 5, 7, 9, 11, 13,
21, 28, 34, 52, 117 post 2
nd inoculation. Blood samples
were obtained by venipuncture using tubes containing
the anticoagulent EDTA and centrifuged at 250 × g for
10 minutes at room temperature. The plasma samples
were collected in 0.5 ml aliquots and stored at -80°C.
Human specimens and MuLV antibodies
A total of 2262 random blood donor specimens (1080
sera and 1182 plasma) were obtained from the Gulf
Coast Regional Blood Center (Houston, TX). All sam-
ples were non-reactive for bloodborne infectious dis-
eases on donor screening tests; these included: HBsAg,
anti-HCV, anti-HBc, anti-HIV-1/HIV-2, HIV-1 NAT,
HCV NAT, anti-HTLV-I/II, Syphilis, West Nile Virus,
and Chagas. Plasma specimens from 100 HIV-1 seropo-
sitive Cameroonian blood donors collected in 2007 in
accordance with local country regulations were provided
by Drs. Lazare Kaptué (Université des Montagnes, Ban-
gangté, Cameroon) and Lutz Gürtler (Max von Petten-
kofer Institute, Ludwig-Maximilian Universität, Munich,
Germany). Plasma specimens from 5 HTLV-I and 5
HTLV-II seropositive US blood donors were obtained
from the Abbott Diagnostics Specimen Bank (Abbott
Park, IL).
Goat polyclonal antibodies included anti-Friend MuLV
(anti-MuLV pAb) and anti-Env (gp69/71) of Rauscher
MuLV (anti-Env pAb) (ATCC, VR-1537AS-Gt and VR-
1521 respectively). Rat monoclonal antibody to gag p30
MuLV was produced at Abbott Diagnostics (Abbott
Park, IL) using hybridoma cells (ATCC, CRL-1912).
Mouse monoclonal antibody to Histidine (anti-His Mab)
was from Abcam plc, (Cambridge, UK).
Western blot analysis
Western blot (WB) strips were produced using sucrose
gradient purified XMRV (ABI) or recombinant proteins.
Virus was lysed with 10 mM Tris-HCl (pH 7.5) buffer
containing 150 mM NaCl and 0.5% Triton at 100° C for
10 min. The viral lysate (80 μg/gel) or recombinant pro-
teins (40-80 μg/gel) were separated by electrophoresis
on a 4-12% NuPAGE Bis-Tris 2-dimension gel (Invitro-
gen, Carlsbad, CA) in the presence of sodium dodecyl-
sulfate (SDS). The protein bands on the gel were
electrophoretically transferred to a polyvinylidene
difluoride (PVDF) membrane (Invitrogen) according to
the manufacture’s instructions.
WB analysis was performed using WesternBreeze kit
reagents (Invitrogen) per the manufacturer’si n s t r u c -
tions. After blocking, the PVDF membrane was cut into
2 mm strips. WB strips were incubated with macaque
sera or human blood donor samples diluted 1:250 (or as
specified) overnight at 2-8°C. Goat anti-MuLV pAb and
anti-Env pAb were diluted 1:1000 and incubated with
WB strips at room temperature for 1 hour. After
removal of unbound antibodies, WB strips were incu-
bated with appropriate alkaline phosphatase conjugated
secondary antibody for 30 minutes at room temperature.
The strips were washed as described and chromogenic
substrate solution was added. Goat anti-human IgM and
IgG (Southern Biotech, Birmingham, AL) alkaline phos-
phatase conjugated secondary antibodies were used to
individually detect IgM and IgG responses to XMRV
infection in the macaque sera.
Competitive inhibition of macaque sera, anti-MuLV
pAb or anti-Env pAb binding to WB strips was per-
formed by pre-incubation of the samples with appropri-
ate recombinant XMRV proteins at room temperature
for 30 minutes to block specific antibodies. WB analysis
was then performed with the pre-absorbed samples as
described above.
For comparing antibody responses, WB strips were
prepared using recombinant proteins (90 pmole/protein/
strip): gp70 (4.4 μg/strip), p15E (4.1 μg/strip) and p30
(3.1 μg/strip). Western blot analysis was then performed
with the primate samples diluted 1:200 as described.
Recombinant proteins
Recombinant proteins derived from XMRV gp70, p15E,
p30, p15, p12 and p10 were expressed in E. coli or HEK
293 mammalian cells (Invitrogen). For gp70 recombi-
nant protein, a fragment containing amino acids (aa) 1-
413 of the surface unit was cloned into an Abbott
Laboratories vector selected for use in a mammalian
protein expression system (Abbott Bioresearch Center,
Worcester, MA) and expressed in DH5a cells (Invitro-
gen). Purified plasmid DNA was then used to transfect
HEK293 cells (Invitrogen). The same sequence was also
cloned into CTP:CMP-3-deoxy-D-manno-octulosonate
cytidylyl transferase (CKS) expression vector, pJO200
(Abbott Diagnostics), and expressed in XL1-Blue cells
(Stratagene, La Jolla, CA) to produce the p70 recombi-
nant protein which lacks glycosylation. For p15E, two
versions of the TM protein were expressed. One version
(aa 1-201) was cloned into PET expression vector pET-
2 8 b( + )( N o v a g e n ,M a d i s o n ,W I )a n de x p r e s s e di n
E. coli BL21 (DE3) cells (Novagen). Another version
with 14 aa deletion in the transmembrane region was
cloned into pJO200 and expressed in XL1-Blue cells.
For p30, the entire CA (aa 1-263) was cloned into both
pJO200 and PL expression vector, pKRR826 (Abbott
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cells, respectively. p15 (aa 1-129 of MA), p12 (aa 1-84 of
p12), and p10, (aa 1-56 of NC) were cloned into pJO200
and expressed in XL1-Blue cells. All recombinant
proteins, except p15E cloned into the pJO200 vector,
contained a 6-histidine tag.
Recombinant proteins produced as insoluble inclusion
bodies within E. coli were solubilized in a solution of
6 M guanidine-HCl, 50 mM Tris-HCl, pH 8.0 and 0.1%
b-mercaptoethanol, clarified by centrifugation and puri-
fied by Sephacryl S-200 size exclusion chromatography
(Pharmacia, Piscataway, NJ). All His tag recombinant
proteins were further purified by His-Bind Nickel Affi-
nity Chromatography (Novagen). The pJO200 expressed
p15E was purified by Sephacryl S-200 size exclusion
chromatography. Purity of all recombinant proteins was
estimated at >90% by scanning densitometry.
Indirect format chemiluminescent immunoassays
The indirect prototype p15E, p70 and p30 antibody
assays were developed on the high-throughput (200
tests/hour) and fully automated ARCHITECT® instru-
ment system (Abbott Diagnostics, Dallas, TX). They are
two-step chemiluminescent immunoassays (CMIAs) that
utilize an indirect (anti-human) assay format (Figure
5 A ) .C a p t u r ea n t i g e n sw e r ep r e p a r e db yc o a t i n gt h eE.
coli-expressed recombinant proteins (p15E, p70 or p30)
onto polystyrene paramagnetic microparticles (Varian,
Inc. Palo Alto, CA). Detection conjugate was prepared
by labelling a goat anti-human IgG (KPL, Inc. Gaithers-
burg, MD) with a chemiluminescent compound, N-
hydroxysuccinimide ester of 10-sulfopropyl-n-tosyl-n-(2-
carboxyethyl)-9-acridinium carboxamide trifluoromethyl
sulfonate (SPCP-acridinium, Abbott Diagnostics). The
acridinium labeled conjugate was purified with high-per-
formance liquid chromatography (HPLC) using Bio-Sil
SEC-250 gel filtration column (Bio-Rad Laboratories,
H e r c u l e s ,C A ) .I nt h ef i r s ts t e po ft h ea s s a y( A d d i t i o n a l
file 2, section B1), a serum or plasma sample (10 μL)
was mixed with specimen diluent buffer (90 μL) and
antigen coated paramagnetic microparticles (50 μL) and
incubated at room temperature (r.t.) for 18 minutes.
During the incubation, the XMRV-specific antibodies
present in the sample were captured on paramagnetic
microparticles. Following incubation, the microparticles
were washed to remove unbound proteins. In the sec-
ond step, acridinium-labeled anti-human IgG conjugate
(50 μL) was added and incubated at r.t. for 4 minutes.
Following an additional wash cycle, alkaline hydrogen
peroxide solution was added to release acridinium che-
miluminescence signal. The intensity of the chemilumi-
nescence, measured as relative light units (RLU) is
proportional to the amount of specific antibody cap-
tured by the recombinant proteins.
Direct format chemiluminescent immunoassays
The prototype direct gp70, p15E and p30 antibody
assays are CMIAs developed for the automated ARCHI-
TECT® instrument system (assay format shown in Figure
5B). The capture antigens were prepared by individually
coating recombinant proteins (E. coli-expressed p15E,
p30 or mammalian-expressed gp70) onto polystyrene
paramagnetic microparticles (Varian). For direct p15E
and p30 CMIAs, detection antigens were prepared by
labeling the p15E protein with N
10-(3-sulfopropyl)-N-(3-
sulfopropyl)-acridinium-9-carboxamide pentaflurophenyl
ester (SPSP-acridinium, Abbott Diagnostics) and the p30
protein with SPCP-acridinium. Both conjugates were
purified with HPLC using Bio-Sil SEC-250 gel filtration
column (Bio-Rad Laboratories). The p15E and p30
CMIAs utilized a two-step assay protocol as depicted in
Scheme B2 (Additional file 2). In the first step of the
assay, a serum or plasma sample (100 μL) was mixed
with specimen diluent buffer (50 μL) and p15E or p30
antigen coated paramagnetic microparticles (50 μL) and
incubated at r.t. for 18 minutes. During the incubation,
the XMRV-specific antibodies present in the sample
were captured on paramagnetic microparticles. Follow-
ing the incubation, the microparticles were washed to
remove unbound proteins. In the second step, 50 μlo f
acridinium-labeled p15E or p30 was added and incu-
bated at r.t. for 4 minutes. Following an additional wash
cycle, alkaline hydrogen peroxide solution was added to
release acridinium chemiluminescence signal. The inten-
sity of the chemiluminescence, measured as relative
light units (RLU) is proportional to the amount of speci-
fic antibody captured by the recombinant proteins p15E
or p30.
For the direct format gp70 CMIA, avidin-biotin com-
plex (ABC) was used to enhance gp70 conjugate
potency. The gp70 protein was labeled with NHS-LC-
LC-Biotin (Thermo Fisher Scientific Inc. Rockford, IL)
and Streptavidin (Leinco Technologies, Inc. St Louis,
Missouri) was labeled with SPCP-acridinium. After puri-
fication by HPLC using Bio-Sil SEC-250 gel filtration
column (Bio-Rad Laboratories), the purified biotinylated
gp70 protein was mixed with purified acridinylated
streptavidin at 1.3:1 molar ratio to form the ABC gp70
conjugate. A one-step assay protocol was utilized to pro-
vide a longer incubation time for the ABC gp70 conju-
gate with anti-gp70 antibodies. In the one-step protocol
(Additional file 2, section B3) a serum or plasma sample
(100 μL), ABC gp70 conjugate (50 μL) and gp70 coated
paramagnetic microparticles (50 μL) were combined and
incubated at r.t. for 22 minutes. During incubation, anti-
gp70 antibodies present in the sample simultaneously
bound to the ABC gp70 conjugate and the gp70 anti-
gen-coated paramagnetic microparticles. Following the
incubation, the microparticles were washed to remove
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nescent signal measurement was performed as described
above.
Additional material
Additional file 1: WB analysis of CMIA reactive blood donor
samples. A1, p15E CMIA reactive blood donor, A2, gp70 CMIA reactive
blood donors and A3 p30 CMIA reactive blood donors were analyzed by
WB with native XMRV viral proteins (4 μg/strip). A4, gp70 CMIA reactive
blood donors were analyzed by WB with mammalian expressed
recombinant gp70 WB. Primate bleed (RIl-10) and anti-MuLV pAb were
used as positive controls.
Additional file 2: Schematic diagrams of XMRV CMIA assay formats.
B1, Indirect (anti-human) 2-step assay format. B2, Direct (double antigen
sandwich) 2-step assay format. B3, Direct (double antigen sandwich) 1-
step assay format. rAgs = recombinant antigens; hv = chemiluminescent
signal.
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